Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 4/20 | 0.67 |
| ▸ | F2 | P00734 | 1/20 | 0.62 |
| ▸ | F10 | P00742 | 1/20 | 0.62 |
| ▸ | F7 | P08709 | 1/20 | 0.62 |
| ▸ | METAP2 | P50579 | 6/20 | 0.58 |
| ▸ | METAP1 | P53582 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CBFB | Q13951 | 9/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517866 | 1.00 | CHEK2 (0.67) | CHEK2F2F10F7METAP2 | |
| SCHEMBL3921720 | 0.90 | CHEK2 (0.83) | CHEK2HPGDKDM4EMAPTALDH1A1 | |
| SCHEMBL30832867 | 0.90 | CHEK2 (0.82) | CHEK2F2F10F7METAP2 | |
| SCHEMBL179109 | 0.88 | METAP2 (0.60) | CHEK2F2F10F7METAP2 | |
| SCHEMBL11034496 | 0.87 | METAP1 (0.58) | CHEK2F2F10F7METAP2 | |
| SCHEMBL6161244 | 0.87 | F2 (0.81) | CHEK2F2F10F7METAP2 | |
| Hydrochloric Acid SCHEMBL23201161 | 0.86 | F2 (0.79) | CHEK2F2F10F7METAP2 | |
| Hydrochloric Acid SCHEMBL30385750 | 0.86 | F2 (0.79) | CHEK2F2F10F7METAP2 | |
| SCHEMBL7402927 | 0.85 | F2 (0.62) | CHEK2F2F10F7METAP2 | |
| SCHEMBL32660751 | 0.84 | CBFB (0.55) | F2F10F7METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274967-A1 | BCAT MODULATION | ICAGEN, LLC | 2022-09-01 | — | — | US | claimed |
| US-20220274967-A1 | BCAT MODULATION | ICAGEN, LLC | 2022-09-01 | — | — | US | disclosed |
| EP-3180004-B1 | CANCER THERAPEUTICS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10562890-B2 | Cancer therapeutics | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-02-18 | — | — | US | disclosed |
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
| EP-3180004-A1 | CANCER THERAPEUTICS | University Of Virginia Patent Foundation (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | disclosed |
| WO-2016025744-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-02-18 | — | — | WO | disclosed |
| US-9221764-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8748618-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2010132684-A9 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010132684-A2 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | CHEK2 1519/4885F2 4705/4885F10 1844/4885 |
| US-20220274967-A1 | BCAT MODULATION | BCAT2, BCAT1, ABAT | CHEK2 2973/4885F2 4009/4885F10 4691/4885 |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CHEK2 1583/4885F2 4004/4885F10 1670/4885 |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CHEK2 1479/4885F2 4019/4885F10 1701/4885 |
| US-10562890-B2 | Cancer therapeutics | RUNX1, CBFB, MCL1 | CHEK2 1519/4885F2 4705/4885F10 1844/4885 |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CHEK2 1479/4885F2 4019/4885F10 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.